Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06802146 · ClinicalTrials.gov registry record · Early Phase 1
Early Intervention in High Risk CCUS
A Early Phase 1 study of Cytopenia and Clonal Cytopenia of Undetermined Significance, sponsored by Lachelle D. Weeks, MD, PhD.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT06802146 is a Early Phase 1 study of Cytopenia and Clonal Cytopenia of Undetermined Significance that is actively recruiting participants, run by Lachelle D. Weeks, MD, PhD. The registered enrollment target is 108 participants, below the 369-participant average among 11 other Cytopenia trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06802146, a Early Phase 1 study of Cytopenia and Clonal Cytopenia of Undetermined Significance, is actively recruiting participants, sponsored by Lachelle D. Weeks, MD, PhD.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to find out more about the potential risks and benefits of early treatment in participants with high risk Clonal Cytopenia of Unknown Significance (CCUS). This study will give eligible CCUS participants the option of either being observed or taking an oral drug as treatment. The names of the study drug involved in this study is: -Decitabine/cedazuridine (DEC/CED) (a nucleoside metabolic inhibitor and cytidine deaminase inhibitor).
Conditions Studied
Interventions
- DRUG Inqovi
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2025-02-07 |
| Est. Completion | 2028-12-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06802146
The ClinicalTrials.gov registry entry for NCT06802146 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 369-participant average among 11 other Cytopenia trials with a reported enrollment target (71% lower). The listed sponsor is Lachelle D. Weeks, MD, PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cytopenia appearing as the primary indexed condition, and to 1 intervention - of which Inqovi is the first listed.
NCT06802146 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06802146 about?
NCT06802146 is a clinical study titled "Early Intervention in High Risk CCUS". This research is being done to find out more about the potential risks and benefits of early treatment in participants with high risk Clonal Cytopenia of Unknown Significance (CCUS). This study will give eligible CCUS participants the option of either being observed or taking an oral drug as treatme...
What is the current status of trial NCT06802146?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 108 participants. The study started on 2025-02-07. Estimated completion is 2028-12-01.
What conditions does trial NCT06802146 study?
This clinical trial studies the following conditions: Cytopenia, Clonal Cytopenia of Undetermined Significance.
What interventions are being tested in trial NCT06802146?
The interventions under investigation include: Inqovi (DRUG).
Who is sponsoring clinical trial NCT06802146?
This trial is sponsored by Lachelle D. Weeks, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06802146 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of a Peripheral Blood Assay to Replace BM Evaluation in Cytopenia - a Multi-Center Observational Study
RECRUITING
-
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
RECRUITING · NA
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Danazol for Treatment of Cytopenias in Patients With Cirrhosis
RECRUITING · Phase 2
-
A Study of Emapalumab for Pediatric Aplastic Anemia
RECRUITING · Phase 2
-
A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia
RECRUITING · Phase 2
Explore more on PlainTrial
Cytopenia
All registered trials for this condition
Clonal Cytopenia of Undetermined Significance
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.